6-Chloro-9-(tetrahydropyran-2-yl)purine, identified by its CAS Registry Number 7306-68-5, stands as a critical building block in advanced pharmaceutical synthesis. Also known by synonyms such as 6-chloro-9-(oxan-2-yl)purine and 6-Chloro-9-(tetrahydro-2H-pyran-2-yl)-9H-purine, this compound is indispensable for the production of vital therapeutic agents.

The chemical structure of 6-Chloro-9-(tetrahydropyran-2-yl)purine is represented by the molecular formula C10H11ClN4O, with a molecular weight of 238.68. Its physical characteristics are consistently observed as a white or off-white crystalline powder. This solid compound exhibits a typical melting point range of 69-77°C, a density of approximately 1.6, and a boiling point around 428.3°C, underscoring its stable nature under standard conditions.

For demanding pharmaceutical applications, the purity of 6-Chloro-9-(tetrahydropyran-2-yl)purine is paramount. High-quality specifications typically mandate a purity of ≥98.0%, as determined by High-Performance Liquid Chromatography (HPLC). Further stringent quality control parameters include a low loss on drying, generally not exceeding 0.5%, and minimal residue on ignition, usually below 0.1%. Strict controls on heavy metal content, kept under 20ppm, ensure its suitability for sensitive pharmaceutical processes and contribute to the overall safety profile of downstream products.

The primary and most significant application of 6-Chloro-9-(tetrahydropyran-2-yl)purine lies in its role as a key intermediate in the synthesis of Idelalisib. Idelalisib is a highly important phosphoinositide 3-kinase (PI3K) inhibitor, an oral medication used in the treatment of specific types of B-cell cancers, including chronic lymphocytic leukemia (CLL), follicular lymphoma (FL), and small lymphocytic lymphoma (SLL). The compound's unique purine structure and chlorination provide the necessary reactive sites and molecular framework crucial for forming the complex Idelalisib molecule. Its consistent quality directly impacts the efficacy and safety of the final drug product.

Beyond its specific role in Idelalisib synthesis, this compound represents a broader class of purine derivatives that are foundational in medicinal chemistry. Its versatility makes it valuable for various research and development initiatives in drug discovery, particularly in oncology and immunology, where purine-based molecules often serve as scaffolds for novel therapeutic agents.

When considering the acquisition of 6-Chloro-9-(tetrahydropyran-2-yl)purine, it is essential to partner with a reliable manufacturer and supplier that adheres to rigorous quality management systems. Such partners provide consistent product quality, robust documentation, and timely delivery. Reputable manufacturers ensure that each batch meets the specified purity and other critical parameters, which is vital for maintaining the integrity and reproducibility of pharmaceutical production processes. Companies seeking to buy or purchase this crucial intermediate should inquire about bulk price options and packaging flexibility. Standard packaging typically includes 25 kg drums, though customized packaging solutions can often be arranged to meet specific customer requirements. Proper storage in a cool, ventilated place, protected from light and moisture, is recommended to preserve the compound's integrity over time.